Characteristics and Outcomes of Initial Virologic Suppressors during Analytic Treatment Interruption in a Therapeutic HIV-1 gag Vaccine Trial

BACKGROUND: In the placebo-controlled trial ACTG A5197, a trend favoring viral suppression was seen in the HIV-1-infected subjects who received a recombinant Ad5 HIV-1 gag vaccine. OBJECTIVE: To identify individuals with initial viral suppression (plasma HIV-1 RNA set point <3.0 log(10) copies/ml...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jonathan Z., Brumme, Chanson J., Lederman, Michael M., Brumme, Zabrina L., Wang, Hongying, Spritzler, John, Carrington, Mary, Medvik, Kathleen, Walker, Bruce D., Schooley, Robert T., Kuritzkes, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316607/
https://www.ncbi.nlm.nih.gov/pubmed/22479542
http://dx.doi.org/10.1371/journal.pone.0034134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316607/
https://www.ncbi.nlm.nih.gov/pubmed/22479542
http://dx.doi.org/10.1371/journal.pone.0034134

Ejemplares similares